BCTX News and Press, BriaCell Therapeutics Corp. From 08/04/22

BriaCell Therapeutics ( NASDAQ: BCTX ) stock rose 5% on Aug. 4 after the company said it secured an exclusive license from University of Maryland, Baltimore County (UMBC) to develop and commercialize Soluble CD80 (sCD80) as a biologic agent to treat cancer. In animal ...

PHILADELPHIA and VANCOUVER, British Columbia, Aug. 04, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”) , a clinical-stage biotechnology company specializing in targeted immunotherapies for ca...

BriaCell Therapeutics ( NASDAQ: BCTX ) on Tuesday said it had entered into an agreement with Waisman Biomanufacturing for Waisman to make BCTX's prostate cancer therapy Bria-Pros. Waisman Biomanufacturing is a contract manufacturing organization at the University of Wi...

Extended survival and tumor shrinkage in advanced breast cancer patients who matched the immunotherapy HLA types, lead to the development of BriaCell’s prostate cancer program based on the patient’s HLA type. Bria-Pros™ is a novel off-the-shelf persona...

BriaCell Therapeutics ( NASDAQ: BCTX ) on Wednesday announced a research collaboration agreement with Harvard Medical School to discover new targets for the development of anti-cancer treatments. The year-long collaboration will focus on the discovery and development of ta...

PHILADELPHIA and VANCOUVER, British Columbia, June 29, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”) , a clinical-stage biotechnology company specializing in targeted immunotherapies for ca...

Anti-Cancer activity of BriaCell’s lead candidate, Bria-IMT™, in advanced breast cancer patients was published in a leading peer-reviewed publication. Bria-IMT™, through a novel mechanism of action, rapidly destroyed tumors in patients who matched Bria...

PHILADELPHIA and VANCOUVER, British Columbia, May 18, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”) , a clinical-stage biotechnology company specializing in targeted immunotherapies for adv...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips BriaCell Therapeutics (NASDAQ: BCTX ) stock is on the move Wednesday morning after getting Fast Track approval from the U.S. Food and Drug Administration (FDA) for Bria-IMT. Source: Shutterstock Bria-IMT is th...

Shares of BriaCell Therapeutics (NASDAQ:BCTX) have added ~7% in premarket trading on Wednesday after the U.S. Food and Drug Administration (FDA) granted a Fast Track status to the clinical-stage biotech company’s lead candidate, Bria-IMT, for the treatment of metastatic breast cancer. ...